secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001104659-25-045324
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics Q1 net loss $8.5M; cash $16.4M; requests EOP2 for Alzheimer's
--------------------------------------------------------------------------------

- Net loss of $8.5M ($0.14 per share) compared to $9.2M ($0.27) in Q1 2024.
- Cash and equivalents $16.4M plus $47M in NIH grants; runway into Q4 2025.
- Requested End-of-Phase 2 meeting with FDA to discuss Alzheimer's SHINE study and registrational trial.
- Phase 2 SHIMMER study in dementia with Lewy bodies accepted for oral presentation at AAIC July 2025.
- Presenting two posters at ARVO on zervimesine's role in regulating lipid metabolism and retinal cell protection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925045324/0001104659-25-045324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925045324/tm2514197d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer